In this article we review the most significant published papers on active surveillance in prostate cancer and present the results of our case series.
We used as main response variables the percentage of patients remaining in surveillance and the oncological results presented as global, cancer specific and metastasis free survivals. Globally, in published series 71.2% of patients included in active surveillance programs, 10-year overall survival is 68% in the series with longer follow up, and cancer-specific survival varies from 97% to 100%. In our series of 144 patients with median follow up of 3.2 years, 76.3% of the patients continue on surveillance. 24 patients (15.9%) stopped surveillance due to histological progression. 5 patients (21.3%) out of the 23 undergoing surgery presented unfavorable pathological criteria on prostatectomy specimen. No patient has died or developed metastases.
Written by:
Llorente C, Diaz Goizueta FJ, Hernandez V, de la Morena JM, de la Peña E. Are you the author?
Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, España.
Reference: Arch Esp Urol. 2014 Jun;67(5):452-6.
PubMed Abstract
PMID: 24914844
Article in Spanish.
UroToday.com Prostate Cancer Section
